A forum for researchers, students and applicants in the field of cyclodextrin technology
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and
This review critically examines how cyclodextrins modulate regulated cell death pathways and the implications for immunometabolism and therapeutic translation. Increasing
Atherosclerosis is a progressive inflammatory disease characterized by the accumulation of lipids in the arterial vessel wall, which begins in
With advanced age, alterations of specific gut-derived metabolites such as aromatic amino acid derivatives might contribute to CVD through prolonged
This review with 238 references explores the multifaceted roles of cyclodextrins in pharmaceutical formulations, ranging from oral, ophthalmic, parenteral, and
The application of CDs in food has been the topic of several review papers. This study with 125 references emphasizes
Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX,
Cholesterol (CHO) is an essential lipid in cell membranes and a precursor for vital living substances. Abnormal CHO levels can
Reactive oxygen species (ROS) contribute to endothelial dysfunction, platelet activation, and coagulation abnormalities, promoting thrombus formation. Given the growing interest
Cardiovascular diseases are disorders that compromise the heart and circulatory systems. Ischemic heart disease is one of the causes of
